Butler Hospital

Dr. Linda Carpenter discusses the new take-home device, Relivion, developed by Neurolief to treat major depressive disorder. The device, currently under FDA review, aims to provide a convenient treatment option for those with treatment-resistant depression, potentially approved in early 2025. Dr. Carpenter highlights the device's potential to revolutionize depression treatment by offering a home-use option, which could significantly improve patient access and convenience.

icobrain aria, an AI-driven MRI software, aids radiologists in detecting ARIA in amyloid immunotherapy patients, improving accuracy for ARIA-E and ARIA-H detection. FDA approved for clinical use on November 7, 2024.

The FDA granted icometrix clearance for icobrain aria, the first AI software to detect, measure, and grade amyloid-related imaging abnormalities (ARIA), a side effect of amyloid-targeting therapies for Alzheimer’s disease. icobrain aria significantly improves ARIA assessment accuracy, enhancing patient safety and facilitating the wider use of these therapies.

icometrix's icobrain aria, the first AI software approved by the FDA for detecting and grading ARIA, enhances ARIA assessment accuracy, ensuring safer use of amyloid-targeting therapies for Alzheimer’s disease. This approval marks a significant advancement in Alzheimer’s care, providing physicians with a tool to make informed treatment decisions and improve patient safety.

FDA approves icobrain aria, the first AI software to detect, diagnose, and monitor Amyloid-Related Imaging Abnormalities (ARIA) in Alzheimer’s patients, enhancing safety of amyloid-targeting therapies.

John Sims presented at CTAD that starting donanemab at low doses and titrating up reduced ARIA-E by 40%, especially for APOE homozygotes. Gil Rabinovici's new donanemab AUR emphasize stricter MRI criteria for safety. Lilly plans to submit data to update the label.

URI Prof. Yalda Shahriari awarded NSF grant to study Parkinson’s hallucinations using VR, aiming to identify neural markers for early detection and their relation to motor functions.

Becker's honors healthcare CNOs for tackling nurse staffing shortages, managing budgets, and developing professional growth opportunities. CNOs oversee nursing departments, spearhead innovative patient care initiatives, and bring clinical expertise and executive leadership skills. The list is based on nominations and editorial research, with leaders presented in alphabetical order.

Blood tests for Alzheimer’s could provide easier, faster diagnosis, paving the way for earlier intervention and treatment. Several tests are under development, with some showing accuracy similar to cerebrospinal fluid tests. FDA approval for such tests is expected within the next 12 months, potentially leading to earlier detection and more effective treatments.